论文部分内容阅读
目的探讨复方斑蝥胶囊联合卡培他滨片治疗晚期结直肠癌的临床疗效。方法选取2014年1月—2016年12月在南京鼓楼医院集团宿迁市人民医院进行治疗的晚期结直肠癌患者60例为研究对象,入组者依据用药的差别分为对照组和治疗组,每组各30例。对照组口服卡培他滨片,1 250 mg/m~2,2次/d,治疗2周,停药1周,3周为1个疗程。治疗组在对照组基础上口服复方斑蝥胶囊,0.75 g/次,2次/d,3周为1个疗程。两组均治疗3个疗程。观察两组的临床疗效,比较两组的肿瘤标志物、生命质量测定量表(QLQ-C30)评分和毒副反应情况。结果治疗后,对照组和治疗组的有效率(ORR)分别为23.33%、50.00%,临床受益率(CBR)分别为53.33%、86.67%,两组比较差异有统计学意义(P<0.05)。治疗后,两组血清癌胚抗原(CEA)、糖类抗原糖链抗原199(CA199)、糖类抗原糖链抗原242(CA242)水平显著下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组躯体、认知、情绪、角色和社会功能评分显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标明显高于对照组,两组比较差异具有统计学意义(P<0.05)。对照组和治疗组毒副反应发生率分别为66.67%、40.00%,两组比较差异有统计学意义(P<0.05)。结论复方斑蝥胶囊联合卡培他滨片治疗晚期结直肠癌具有较好的临床疗效,可改善患者生存质量,降低肿瘤标志物水平,安全性较好,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of compound cantharidin capsules combined with capecitabine in the treatment of advanced colorectal cancer. Methods From January 2014 to December 2016, 60 patients with advanced colorectal cancer who were treated in Nanjing Drum Tower Hospital, Suqian People’s Hospital were enrolled in this study. The participants were divided into control group and treatment group according to the difference of medication. Group of 30 cases. Control group oral capecitabine tablets, 1 250 mg / m ~ 2,2 times / d, treatment for 2 weeks, withdrawal for 1 week, 3 weeks for a course of treatment. Treatment group on the basis of the control group oral compound cantharidin capsules, 0.75 g / time, 2 times / d, 3 weeks for a course of treatment. Both groups were treated 3 courses. The clinical efficacy of the two groups was observed. The tumor markers, quality of life scale (QLQ-C30) and toxicity were compared between the two groups. Results After treatment, the effective rates (ORR) of the control group and the treatment group were 23.33% and 50.00%, respectively. The clinical benefit rates (CBR) were 53.33% and 86.67% respectively. There was significant difference between the two groups (P <0.05) . After treatment, the levels of CEA, CA199 and CA242 in the two groups were significantly decreased (P <0.05), and the differences were statistically significant (P <0.05). The observation group of the treatment group was significantly lower than the control group, the difference was statistically significant (P <0.05). After treatment, the somatosensory, cognitive, emotional, role and social function scores of the two groups were significantly increased, with statistical significance (P <0.05) before and after treatment in the two groups; and these indexes in the treatment group were significantly higher than those in the control group The difference was statistically significant (P <0.05). The incidences of side effects in control group and treatment group were 66.67% and 40.00%, respectively, with significant difference between the two groups (P <0.05). Conclusions Compound cantharidin capsule combined with capecitabine tablet has good clinical curative effect on advanced colorectal cancer, which can improve the quality of life of patients and reduce the level of tumor markers, which is safe and has certain clinical application value.